•
Sep 30, 2022

Natera Q3 2022 Earnings Report

Natera reported a strong quarter with record volumes and continued progress on key clinical and data milestones.

Key Takeaways

Natera reported a 33.2% increase in total revenues, reaching $210.6 million in Q3 2022 compared to $158.1 million in Q3 2021. The growth was driven by a 29.8% increase in product revenues, totaling $199.8 million, and a 27.1% increase in test volumes, with approximately 517,500 tests processed.

Total revenues increased by 33.2% to $210.6 million compared to Q3 2021.

Product revenues increased by 29.8% to $199.8 million compared to Q3 2021.

Approximately 517,500 tests were processed, a 27.1% increase compared to Q3 2021.

Net loss was $121.5 million, or ($1.25) per diluted share, compared to a net loss of $151.3 million, or ($1.63) per diluted share, for the same period in 2021.

Total Revenue
$211M
Previous year: $158M
+33.2%
EPS
-$1.25
Previous year: -$1.63
-23.3%
Tests Processed
517.5K
Previous year: 407.3K
+27.1%
Tests Accessioned
502.9K
Previous year: 394.2K
+27.6%
Total Tests Reported
483K
Previous year: 373.1K
+29.5%
Gross Profit
$94.1M
Previous year: $76.7M
+22.7%
Cash and Equivalents
$521M
Previous year: $1B
-47.9%
Free Cash Flow
-$114M
Previous year: -$104M
+9.8%
Total Assets
$1.01B
Previous year: $1.31B
-23.0%

Natera

Natera

Forward Guidance

Natera anticipates 2022 total revenue of $810 million to $830 million; 2022 gross margin to be approximately 44% to 47% of revenues; selling, general and administrative costs to be approximately $575 million to $590 million; research and development costs to be $320 million to $340 million, and net cash consumption to be approximately $450 million.